Whether your cancer is common or rare, the doctors at Sylvester Comprehensive Cancer Center are doing the research to create better treatments, and The Pap Corps is proud to support them! Jonathan C Trent, M.D., Ph.D. is a professor of medicine, associate director for clinical research, and director of the Bone and Soft-Tissue Sarcoma Group at Sylvester Comprehensive Cancer Center. He is also the associate director for clinical research at Sylvester. Dr. Trent's research focuses on the clinical and translational aspects of sarcomas, including gastrointestinal stromal tumors (GISTs) and chondrosarcomas. He has been involved in numerous clinical trials aimed at improving treatment outcomes for patients with these rare cancers. His work has contributed to the development of new therapies and has enhanced the understanding of the molecular mechanisms underlying sarcoma pathogenesis. Dr. Trent's dedication to both patient care and research has made him a leading figure in the field of sarcoma oncology. (fb)

The Pap Corps supports the next survivor by our incredible fundraising for Sylvester Comprehensive Cancer Center. Today, we honor C. Ola Landgren, M.D., Ph.D., chief of the Division of Myeloma and director of the Sylvester Myeloma Institute, who is revolutionizing multiple myeloma care. His groundbreaking research may speed up drug approval timelines and enhance therapeutic strategies to deliver better outcomes for patients. Dr. Landgren is also advancing precision medicine at Sylvester by combining MRD testing with genomic profiling. This enables personalization of treatments based on individual tumor genetics. This tailored approach is challenging the traditional use of therapies like stem cell transplants, with emerging technologies like CAR T-cell therapy and bispecific monoclonal antibodies potentially replacing them for some patients, for improved outcomes. (fb)